Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Interneuron, Eli Lilly deal

IPIC received an undisclosed milestone upon Lilly's completion of

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE